BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29368793)

  • 1. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
    Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
    Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
    Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis.
    Lavon I; Heli C; Brill L; Charbit H; Vaknin-Dembinsky A
    Front Immunol; 2019; 10():835. PubMed ID: 31134049
    [No Abstract]   [Full Text] [Related]  

  • 5. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
    Esen F; Deniz G; Aktas EC
    Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].
    Nie L; Liu XY; Ma RJ; Yuan XL; Jiang L; Yang J; Hu AX; Li Z; Zhu ZM
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):598-602. PubMed ID: 34455749
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
    Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
    Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study.
    Jin S; Shang Z; Wang W; Gu C; Wei Y; Zhu Y; Yang C; Zhang T; Zhu Y; Zhu Y; Wu J; Ye D
    J Immunother; 2023 May; 46(4):154-159. PubMed ID: 37017991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.
    Tassi E; Grazia G; Vegetti C; Bersani I; Bertolini G; Molla A; Baldassari P; Andriani F; Roz L; Sozzi G; Pastorino U; Mortarini R; Anichini A
    Cancer Res; 2017 Feb; 77(4):851-861. PubMed ID: 27979840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
    Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.
    Fromentin R; Bakeman W; Lawani MB; Khoury G; Hartogensis W; DaFonseca S; Killian M; Epling L; Hoh R; Sinclair E; Hecht FM; Bacchetti P; Deeks SG; Lewin SR; Sékaly RP; Chomont N
    PLoS Pathog; 2016 Jul; 12(7):e1005761. PubMed ID: 27415008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
    Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
    Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The expression and correlation analysis of TOX and inhibitory receptors on peripheral blood CD8
    Yan L; Yang JR; Wang HQ; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2095-2099. PubMed ID: 37455127
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of TIM-3 and LAG-3 in extranodal NK/T cell lymphoma, nasal type.
    Feng Y; Zhong M; Liu Y; Wang L; Tang Y
    Histol Histopathol; 2018 Mar; 33(3):307-315. PubMed ID: 28901003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
    Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
    Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
    Anderson AC; Joller N; Kuchroo VK
    Immunity; 2016 May; 44(5):989-1004. PubMed ID: 27192565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.
    Fleury M; Belkina AC; Proctor EA; Zammitti C; Simms RW; Lauffenburger DA; Snyder-Cappione JE; Lafyatis R; Dooms H
    Arthritis Rheumatol; 2018 Apr; 70(4):566-577. PubMed ID: 29245183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.